<DOC>
	<DOCNO>NCT00006221</DOCNO>
	<brief_summary>Phase I trial study effectiveness BMS-247550 treating patient malignant solid tumor lymphoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Advanced Cancers</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose BMS-247550 patient advanced malignancy . II . Determine qualitative quantitative toxic effect regimen patient . III . Determine pharmacokinetics pharmacodynamics regimen patient . IV . Determine antitumor effect regimen patient . OUTLINE : This dose-escalation study . Patients stratify accord prior therapy ( heavily pretreated v minimally pretreated ) . Patients receive BMS-247550 IV 1 hour weekly week 1-4 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-247550 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat dose level . Patients treat MTD receive treatment weekly week 1-3 4-week course . Patients follow within 1 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor lymphoma potentially curative therapeutic option exist demonstrates increase survival ( consider tumor type , stage , number prior regimen ) No symptomatic brain metastasis require dexamethasone No progression cerebral edema CT scan MRI within past 4 week PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Neutrophil count least 1,500/mm^3 Hemoglobin least 8.5 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No atrial ventricular arrhythmia require medication No ischemic event within past 6 month Other : No preexist peripheral neuropathy great grade 1 No serious medical illness active infection would preclude study participation No dementia , psychiatric illness , alteration mental status would preclude study compliance No active malignancy except curatively treat basal cell skin cancer carcinoma situ cervix No history allergy hypersensitivity reaction paclitaxel Cremophor ELcontaining compound Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study completion PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : At least 4 week since prior anticancer hormonal therapy recover No concurrent hormonal therapy except LHRH agonist noncastrated prostate cancer , contraceptive , hormone replacement therapy ( e.g. , conjugated estrogen ) , megestrol appetite stimulant Radiotherapy : At least 4 week since prior radiotherapy recover Concurrent palliative radiotherapy limit site allow Surgery : At least 4 week since prior surgery recover Other : At least 30 day since prior investigational agent recover No concurrent experimental medication No concurrent antiretroviral ( HAART ) therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>